Edwards F R, Whitwell F
Thorax. 1974 Nov;29(6):654-8. doi: 10.1136/thx.29.6.654.
, , 654-658. Cell-mediated immunity to cancer cells would appear to exert some control over the extension of tumour growth, and stimulation of this factor might result in increased survival after surgical treatment of the tumour. Of the various agents used as stimulators in experimental work, BCG would seem to be the most convenient to use in man. A single dose of BCG-Glaxo (500,000 organisms) was given subdermally 10 days after excision of lung carcinoma. The length of survival was used as the index of the effect of the BCG. Two trials were initiated, the first to study the safety of BCG and a survival study of 120 consecutive cases (60 used as controls). This is an interim report at two years of this trial. The main features at this stage show that the overall survival rate has increased from 38% in the controls to 52% in the BCG group. In the squamous-cell group survival has risen from 50% to 62% and, in those with positive nodes, from 33% to 53%. In the oat-cell group, two-year survival has risen from 11% in the controls to 50% in the BCG groups, though the numbers are small. Although encouraging, the results are not statistically significant. The second trial is a randomized trial in which five surgeons have taken part, and 500 consecutive cases of lung resection for carcinoma are documented (250 control and 250 BCG). It is too early for results to be assessed in this group. It is hoped that at three, four, and five years more favourable survival figures will be obtained.
, , 654 - 658. 对癌细胞的细胞介导免疫似乎对肿瘤生长的扩展有一定控制作用，刺激这种因素可能会提高肿瘤手术治疗后的生存率。在实验工作中用作刺激剂的各种药物中，卡介苗在人体中似乎是最便于使用的。在肺癌切除术后10天，皮下注射单剂量的葛兰素卡介苗（500,000个菌体）。生存时间被用作卡介苗效果的指标。启动了两项试验，第一项试验研究卡介苗的安全性以及对120例连续病例（60例作为对照）的生存研究。这是该试验两年时的中期报告。现阶段的主要特征表明，总体生存率已从对照组的38%提高到卡介苗组的52%。在鳞状细胞组中，生存率从50%提高到62%，在有阳性淋巴结的患者中，从33%提高到53%。在燕麦细胞组中，两年生存率从对照组的11%提高到卡介苗组的50%，不过病例数较少。尽管结果令人鼓舞，但在统计学上并不显著。第二项试验是一项随机试验，有五位外科医生参与，记录了500例连续的肺癌切除术病例（250例对照和250例卡介苗组）。对该组结果进行评估还为时过早。希望在三年、四年和五年时能获得更有利的生存数据。
